Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - Pharmaceutical News - Aspen's shares slide on supply allegations [BusinessReport (South Africa)] - April 23, 2017

Pharmacy News Article

 4/19/17 - Aspen's shares slide on supply allegations [BusinessReport (South Africa)]

Cape Town - Aspen shares fell sharply on Tuesday as the branded and generic pharmaceutical products group moved to water down allegations that it withheld life-saving drugs to drive up prices by 4 000 percent in some of its Spanish market.

Aspen shares fell 4.14 percent to close at R268.50 on the JSE, after reports in the UK surfaced about the pharmaceutical's internal memo, which indicated that the company considered destroying its own stockpiles of vital cancer treatment medication in order to raise prices.

On Tuesday, the company said in a terse statement that it would not respond on the merits of the allegations as the matter was sub judice.

Share this story

Pharmaceutical giant Aspen is alleged to have withheld stockpiles of vital cancer drugs to raise prices. Photo: Simphiwe Mbokazi

Aspen did shed some light on its position in the matter, saying it had a track record of supplying affordable and quality medication.

The supply of the oncology products in question is no exception, the multinational company said. Aspen's status as a responsible and committed provider of quality, affordable medicines is further validated by the role it has played in saving millions of lives across Africa, through pioneering and supplying generic antiretroviral medicine in Africa for the treatment of HIV/Aids.

Aspen operates with an established business presence in about 50 countries spanning six continents and employs more than 10000 people.

It operates 26 manufacturing facilities across 18 sites and has a market capitalisation of about $10 billion (R133 billion), making it the largest pharmaceutical company listed on the JSE.

According to internal e-mails by Aspen reported on by the Times of London, the company began withholding five cancer drugs from the market in Spain in May 2014, forcing patients to search elsewhere for replacement drugs.

The alleged withholding of the medication came after the Spanish health ministry did not agree to the substantial price hikes proposed by Aspen.

The company acquired the five cancer drugs from British firm GlaxoSmithKline (GSK) in 2009 as a part of a deal worth 273 million (R4.6 billion). As part of the transaction, GSK acquired 16percent of Aspen-GSK and agreed to divest eight of its specialist medications in Aspen.

The products divested by GSK in Aspen included chemotherapy drugs Alkeran and Purinethol Leukemia treatments Lanvis and Mcleran. Aspen said the oncology portfolio brought into question by The Times formed only a small part of its revenue.

The oncology portfolio in question generated revenue in the EU in Aspen's financial year ended June 30, 2016 of 60 million euros (R854 million).

"The majority of the revenue was from the sale of tablets which have an average price of about 2 per tablet, the company said.

The group posted total revenue of R35.6 billion in that time.

Asief Mohamed, chief investment officer at Aeon Investment Management, which holds Aspen stock, said it was disappointing that the company was accused of being involved in such behaviour.

We are disappointed that Aspen seems to have used its monopoly position to disadvantage terminally ill patients in the long run such behaviour would have a material negative impact on its share price, Mohamed said.

But Spain has not been the only European country targeting Aspen's price gouging on the continent, as the group has found itself in competition authorities crosshairs recently.

Last year, the Italian Competition Authority (ICA) imposed a $5.5 million fine on the company for infringing article 102a of the Treaty on the Functioning of the European Union.

According to the ICA, Aspen fixed unfair prices with increases up to 1500 percent for life-saving and irreplaceable drugs in the treatment of oncohematological patients, especially children and the elderly.

BUSINESS REPORT



(c) BusinessReport 1999 - 2017 Independent Newspapers (Pty) Limited. All rights strictly reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Apr 24: A Look Inside the Top 200 Drugs
Apr 25: Skin Infections: Focus on Cellulitis & MRSA
Apr 26: Medical Marijuana: Examining the Science, Not the Politics
Apr 27: What's New? New Treatments for Type 2 Diabetes
Apr 30: Using Effective Communication to Reduce Medication Errors
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415